Sorafenib-Induced Acute Pancreatitis: Case Report and Review of the Literature

  • Patrick Twohig
  • Jaclyn Rivington
Case Report


Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is the third leading cause of cancer-related death worldwide [1]. The reported annual incidence of HCC is rising in most countries, mostly due to the increasing burden of chronic hepatitis B and hepatitis C virus (HCV), along with the prevalence of other risk factors such as excessive alcohol consumption. Although new HCV therapies have proven effective, they are often expensive and not always universally accessible. Additionally, the increased incidence of non-alcoholic fatty liver disease secondary to obesity and diabetes contribute to new cases of HCC, especially in developed countries such as the USA [2, 3, 4].

The Barcelona Clinic Liver Cancer (BCLC) Classification is the gold-standard guideline for managing patients with HCC [5]. Early stages of HCC can be successfully managed with different treatment modalities, including hepatic resection, liver transplantation, and ablative therapies....



No funding was provided for the publication of this article, and the authors report no conflicts of interest.

Compliance with Ethical Standards


Informed consent was obtained from the patient for publication of this case report and any accompanying images.


  1. 1.
    DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995 -. Record No. 113622, Hepatocellular carcinoma; [updated 2016 Feb 15, cited February 9, 2017]; [about 24 screens]. Available from Registration and login required.Google Scholar
  2. 2.
    Li M, Srinivas S. Acute pancreatitis associated with sorafenib. South Med J. 2007;100(9):909–11.CrossRefPubMedGoogle Scholar
  3. 3.
    Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–109.CrossRefPubMedGoogle Scholar
  4. 4.
    Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23:965–72.CrossRefPubMedGoogle Scholar
  5. 5.
    Fitzmorris P, Shoreibah M, Anand BS, Singal AK. Management of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2015;141(5):861–76.CrossRefPubMedGoogle Scholar
  6. 6.
    Mousa AB. Sorafenib in the treatment of advanced hepatocellular carcinoma. Saudi J Gastroenterol. 2008;14(2):40–2.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Saadati H, Saif MW. Sorafenib-induced acute pancreatitis. JOP. 2010;11(3):283–4.PubMedGoogle Scholar
  8. 8.
    Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.CrossRefPubMedGoogle Scholar
  9. 9.
    Badalov N, Baradarian R, Iswara K, et al. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol. 2007;5:648–61.CrossRefPubMedGoogle Scholar
  10. 10.
    Llovet J, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). Proceedings from the American Society of Clinical Oncology Conference: Chicago, IL; 2007.Google Scholar
  11. 11.
    Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007;12:426–37.CrossRefPubMedGoogle Scholar
  12. 12.
    Chou JW, Cheng KS, Huang CW. Sorafenib-induced acute pancreatitis: a case report and review of the literature. Intern Med. 2016;55:623–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Amar S, Wu KJ, Tan WW. Sorafenib-induced pancreatitis. Mayo Clin Proc. 2007;82:521.CrossRefPubMedGoogle Scholar
  14. 14.
    Kobayashi Y, Kanemitu T, Kamoto A, et al. Painless acute pancreatitis associated with sorafenib treatment: a case report. Med Oncol. 2011;28:463–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Sevin A, Chen A, Atkinson B. Tyrosine kinase inhibitor induced pancreatitis. J Oncol Pharm Pract. 2012;19(3):257–60.CrossRefPubMedGoogle Scholar
  16. 16.
    Olayode A, Kizer R. Acute pancreatitis secondary to sorafenib use. Am J Gastroenterol. 2013;108(1):S262.Google Scholar
  17. 17.
    Wang HE, Chen CT, Huang HH. Sorafenib-induced acute pancreatitis. J Med Sci. 2014;34:126–8.CrossRefGoogle Scholar
  18. 18.
    Reig M, Forner A, Rimola J, de Lope CR, Ayuso C, Llovet JM, et al. 815 sorafenib for the treatment of advanced hepatocellular carcinoma. Feasibility and safety outside research trials. J Hepatol [Internet]. European Association for the Study of the Liver. 2009;50:Se298. Available from: Google Scholar
  19. 19.
  20. 20.
    Hameed AM, Lam VWT, Pleass HC. Significant elevations of serum lipase not caused by pancreatitis: a systematic review. HPB. 2015;17(2):99–112.CrossRefPubMedGoogle Scholar
  21. 21.
    Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290:H560–76.CrossRefPubMedGoogle Scholar
  22. 22.
    Klar E, Messmer K, Warshaw AL, et al. Pancreatic ischaemia in experimental acute pancreatitis: mechanism, significance and therapy. Br J Surg. 1990;77:1205–10.CrossRefPubMedGoogle Scholar
  23. 23.
    Ueda T, Takeyama Y, Yasuda T, et al. Vascular endothelial growth factor increases in serum and protects against the organ injuries in severe acute pancreatitis. J Surg Res. 2006;134:223–30.CrossRefPubMedGoogle Scholar
  24. 24.
    Ferrario C, Strepponi I, Esfahani K, Charamis H, Langleben A, Scarpi E, et al. Phase I/II trial of sorafenib in combination with vinorelbine as first-line chemotherapy for metastatic breast cancer. PLoS One 2016;11(12):1–14.Google Scholar
  25. 25.
    Kitamura Y, Yoshii H, Nishimoto K, Shinchi Y, Tokonabe S, Takao M, et al. A case of pancreatic side effects resulting from sorafenib and axitinib treatment of stage IV renal cell carcinoma. Keio J Med. 2015;64(4):62–4.Google Scholar
  26. 26.
    Péron J, Khenifer S, Potier V, et al. Axitinib-induced acute pancreatitis: a case report. Anti-Cancer Drugs. 2014;25:478–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Pezzilli R, Corinaldesi R, Morselli-Labate AM. Tyrosine kinase inhibitors and acute pancreatitis. JOP. 2010;11:291–3.PubMedGoogle Scholar
  28. 28.
    Kawakubo K, Hata H, Kawakami H, Kuwatani M, Kawahata S, Kubo K, et al. Pazopanib-induced severe acute pancreatitis. Case Rep Oncol. 2015;8:356–8.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Jain L, Woo S, Gardner ER, et al. Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol. 2011;72:294–305.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Saba University School of MedicineThe Bottomthe Netherlands
  2. 2.MetroHealth Medical CenterClevelandUSA

Personalised recommendations